Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"The Melligen cells reversed the diabetic condition" This is incredible to me.
"In an effort to avoid the use of non-human islet cells in its diabetes treatment, PharmaCyte has obtained from the University of Technology Sydney (UTS) in Australia an exclusive, worldwide license to use insulin-producing genetically engineered human liver cells developed by UTS to treat Type 1 diabetes and insulin-dependent Type 2 diabetes. These cells, named “Melligen,” have already been tested in mice and shown to produce insulin in direct proportion to the amount of glucose in their surroundings. In fact, when Melligen cells were transplanted into immosuppressed diabetic mice, their blood glucose levels became normal. The Melligen cells reversed the diabetic condition."
You know what, you are absolutely correct. My apologies. I misinterpreted your post. My bad..please except.
Upgraded to a pivotal trial, fast track, more patients, more time. Sooner to market. Too easy
All evidence suggest yes to IND filing. But you say maybe, Its so confusing, i wonder who I should believe.
Yea, its getting too easy as the company strengthens.
it is?
But if I must :
"Dr. Stephen Gately: “New and effective therapies for patients with pancreas cancer are clearly needed. We have reviewed PharmaCyte’s prior human clinical data and are encouraged that this approach may provide clinical benefit for patients with pancreas cancer."
Why am I doing your dd for you? Be patient. Its all coming to fruition. Imagine the good that could be done by this treatment. I bet our Diabetes treatment will be a blockbuster. I to am excited for the upcoming IND for PC. Its a pivotal trial you know.
So many great doctors are risking their reputations on this treatment. Its amazing the rock stars in the medical world we have attracted. Including Von Hoff who has conducted OVER 200 clinical trials. If the IND is so mythical. Why is this great doctor and others associating themselves with this treatment? And why such strong constant opposition. Pivotal trial means we go to market if its successful. We had the pre IND meeting with the FDA. They suggested we expand our trial to a much larger pivotal trial. Great doctors, like wise investors want to be associated with breakthroughs, its their legacy. I have read every piece of information that I can find. I am with Drs Von Hoff, Lohr, Hidalgo, Scher, Makowka, Crabtree on this one. Go PMCB!! IMHO
I have been watching this for a while, just started buying in. This one has a good chance in my humble opinion. They are doing a Great job branding. We are all aware of the banking issues that confront MJ companies, but this will eventually be the dam that bursts. TRTC is a known entity with a great brand and has distribution networks established. When the eventual rescheduling of MJ occurs this will be a huge advantage. Anyone considering a penny should understand it is a high risk environment, but this one I believe is worth the risk. When the dam does burst, i believe the debt TRTC has will not be of consequence. IMHO
I agree, I think we will get news on our diabetes treatment after we file for our IND for Pancreatic cancer. Everyone here knows the value of diabetes treatment! You will continue to here a lot more talk on diabetes for the next coming months. I believe we could see concurrent clinical trials for Cell in a Box. Pancreatic Cancer and diabetes.
I hope they don't hurry, we want this Pivotal trial done right. When the FDA suggested a pivotal trial, which is a fast track, it increased the trial size. These trials are so crucial that everything must be done exactly right. This takes time. I am confident that we will have this IND filed when they have all the preparations taken care of. Many of us who closely follow the company believe other huge news is on the way. Do your own DD. Make your own decisions. I usually move along when I decide something is not a good investment for me.
false
What has not been touched on recently is this treatment is chemo WITHOUT side effects. This has a chance to make an inoperable tumor operable. Unfortunately there are a lot of people with PC cancer. In the United States, the American Cancer Society reports that approximately 48,960 people are diagnosed with pancreatic cancer and about 40,560 people die from the disease each year. We only need 200 patients. I do not think finding people who need our help will be a problem unfortunately.
So you are pumped for the upcoming filing of the IND for our pivotal trial for Pancreatic Cancer, Me as well.
Is that all u got. Where is the red flag. Lol
Thanks Rudy
"they keep spreading fake stories" LOL
I have only been here a year or so, but I know I want better treatment for Pancreatic Cancer and Diabetes. I know our CEO has fought quite a battle to get this to FDA which he has. I know from past trials this treatment has massive potential for a medical game changer. I also know that when PMCB starts making money other companies will stop making money. And I am thankful that I have realized that it is a strong person who builds something positive and a weak person to tear it down. I wish you all the luck in the future.
The same information every day
Oh yes, I can recognize a liar a mile away.
They can't end a partnership because we own part of them. We had our Pre IND meeting with the FDA and they recommended a pivotal trial. This is a fast track! This pivotal and much larger trial takes time to prepare for. Once we file our IND, the trial will start 30 days later. I contacted Investor relations(which I do frequently) , and they are on track to file the IND this year.
really
"they keep spreading fake stories" LOL
"they keep spreading fake stories" LOL
Well, its going to be an interesting Fall for PMCB. IND for pivotal trial coming soon. There is some evidence suggesting a Janssen partnership. But its the diabetes. Diabetes will be huge and I think this may have some big pharma scared.
incorrect info
Someone posted Capricorns 5 year chart showing the effect of the Janssen partnership on the pps. It went up 10 fold. That would put us at .70 if we experienced the same scale reaction. That would be a nice start to Kaboom. A great launching point for more news.
If it is 30$, i will never look at prices on the menu again. Monte Rosso vineyard Cabernet for all longs.
I agree Brian. They can vet the technology better than we can and they signed on. Big news definitely coming.
Pj, I am pretty sure if we enter an agreement with a larger company loaded with cash they will be funding us. This is outside agreements we have with others
I just found this interesting. This is what Bavarian Nordic is getting with their collaboration with Janssen, from the Janssen website:
"Bavarian Nordic will receive an upfront payment and be eligible to receive milestone payments based upon the achievement of specified development, regulatory and sales milestones and tiered royalties on future worldwide sales."
Just wondering if we might get a similar structured deal?
Dr Hidalgo, some facts;
" Dr. Hidalgo joined the Johns Hopkins University Kimmel Cancer Center in 2001 where he stayed, as co-director of the drug development program, and GI Programme until 2009. In 2003, Dr. Hidalgo and other colleagues founded the Pancreatic Cancer Research Team (PCRT), a cooperative clinical trials group that focuses on novel Therapeutics for patients with pancreatic cancer. Dr. Hidalgo joined the CNIO in 2009 to lead a Unit in Clinical Research in GI Cancer. Dr. Hidalgo has participated in the clinical development of more than 20 new agents including recently approved drugs such as erlotinib and temsirolimus. He has published more than 160 papers in peer review journals and his work has been funded uninterruptedly by the NCI, AACR, and ASCO and other funding agencies. His most recent efforts focus in novel therapeutic for pancreatic cancer."
On Von Hoff, from the article I posted earlier:
"He has been involved in the development of a half-dozen drugs that are routinely used to treat cancer, drugs that have extended people's lives by months and sometimes years.
In the quest to create the most effective medicine, he has worked with other scientists over the years on more than 200 clinical trials, which some cancer researchers say is probably a record.
The breadth of the research has made Von Hoff one of the foremost cancer scientists in the world. In June, the American Society of Clinical Oncology honored him with its most prestigious award in the field of cancer research."
Read more: http://archive.azcentral.com/arizonarepublic/news/articles/2010/08/08/20100808valley-cancer-doctor.html#ixzz4ouCriPoj
Dr. Sher has participated in the surgery and management of more than 700 patients. She has been the Principal or Co-Principal Investigator for more than 50 clinical trials and has mentored young faculty at USC in the conduct of clinical trials. Dr. Sher is active in the clinical and basic science research components of the Abdominal Organ Transplantation Program at USC. She has authored or co-authored publications on immunosuppression, chronic rejection, disease recurrence, infection, and prophylaxis and hepatobiliary surgery. Dr. Sher is one of the original editors of Current Opinion in Organ Transplantation, which provides the reader with an up to date overview of the entire field of organ transplantation.........
Brings nothing to the table?
Dr Scher has been involved in over 50 clinical trials and some say she brings nothing to the table? A position not supportable.
Heavy on the noise today, good news coming!
Mr Waggoner on the appointee of DR Scher;
“Not only will Dr. Sher be a key member of the senior management team, she will oversee our entire clinical research program. Dr. Sher has been the Principal or Co-Principal Investigator on more than 50 clinical trials. This experience is invaluable to PharmaCyte. Dr. Sher is expected to contribute considerably to our success as a biotech company and, most importantly, to a successful pivotal trial in pancreatic cancer.”
- She will oversee the research program
- She has been involved in over 50 trials
-Why would such a distinguished, credible Dr agree to work at PharmaCyte? Because she wants to be part of something huge, cure people of deadly diseases, meet an unmet medical need!
This is from the interview with DR Stephen Gately, President of TD2:
TD2 has been involved in many clinical trials. What are your early impressions of PharmaCyte's pancreatic cancer therapy?
Dr. Stephen Gately: “New and effective therapies for patients with pancreas cancer are clearly needed. We have reviewed PharmaCyte’s prior human clinical data and are encouraged that this approach may provide clinical benefit for patients with pancreas cancer. TD2 is grateful for the opportunity to work with PharmaCyte’s team on this exciting project.”
http://ir.pharmacytebiotech.com/press-releases/detail/134/pharmacyte-biotech-discusses-patient-enrollment-and-td2s
I have heard nothing but excitement from longs here since the pre IND meeting. Its going to be a great Fall! PMCB!